25 XP   0   0   10

Iterum Therapeutics PLC
Buy, Hold or Sell?

Let's analyse Iterum Therapeutics PLC together

PenkeI guess you are interested in Iterum Therapeutics PLC. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Iterum Therapeutics PLC. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Iterum Therapeutics PLC

I send you an email if I find something interesting about Iterum Therapeutics PLC.

Quick analysis of Iterum Therapeutics PLC (30 sec.)










What can you expect buying and holding a share of Iterum Therapeutics PLC? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-0.48
Expected worth in 1 year
$-3.04
How sure are you?
27.6%

+ What do you gain per year?

Total Gains per Share
$-2.56
Return On Investment
-165.2%

For what price can you sell your share?

Current Price per Share
$1.55
Expected price per share
$1.26 - $2.5
How sure are you?
50%

1. Valuation of Iterum Therapeutics PLC (5 min.)




Live pricePrice per Share (EOD)

$1.55

Intrinsic Value Per Share

$-25.54 - $-29.98

Total Value Per Share

$-26.02 - $-30.46

2. Growth of Iterum Therapeutics PLC (5 min.)




Is Iterum Therapeutics PLC growing?

Current yearPrevious yearGrowGrow %
How rich?-$6.4m$38.2m-$32.4m-562.2%

How much money is Iterum Therapeutics PLC making?

Current yearPrevious yearGrowGrow %
Making money-$9.5m-$11.1m$1.5m15.8%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Iterum Therapeutics PLC (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#933 / 1010

Most Revenue
#759 / 1010

Most Profit
#555 / 1010

Most Efficient
#206 / 1010

What can you expect buying and holding a share of Iterum Therapeutics PLC? (5 min.)

Welcome investor! Iterum Therapeutics PLC's management wants to use your money to grow the business. In return you get a share of Iterum Therapeutics PLC.

What can you expect buying and holding a share of Iterum Therapeutics PLC?

First you should know what it really means to hold a share of Iterum Therapeutics PLC. And how you can make/lose money.

Speculation

The Price per Share of Iterum Therapeutics PLC is $1.55. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Iterum Therapeutics PLC.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Iterum Therapeutics PLC, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.48. Based on the TTM, the Book Value Change Per Share is $-0.64 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.41 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Iterum Therapeutics PLC.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.92-59.4%-0.76-48.9%-0.83-53.3%-1.24-79.7%-1.16-74.8%
Usd Book Value Change Per Share-0.73-47.2%-0.64-41.3%-0.41-26.7%-0.29-18.7%-0.02-1.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.73-47.2%-0.64-41.3%-0.41-26.7%-0.29-18.7%-0.02-1.1%
Usd Price Per Share1.97-1.21-0.75-2.18-2.27-
Price to Earnings Ratio-0.54--0.45--0.30--0.33--0.36-
Price-to-Total Gains Ratio-2.69--2.08--1.99--1.68--1.64-
Price to Book Ratio-4.13-0.43-0.31--0.94--0.54-
Price-to-Total Gains Ratio-2.69--2.08--1.99--1.68--1.64-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.55
Number of shares645
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.64-0.29
Usd Total Gains Per Share-0.64-0.29
Gains per Quarter (645 shares)-412.89-187.29
Gains per Year (645 shares)-1,651.55-749.16
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1652-16620-749-759
20-3303-33140-1498-1508
30-4955-49660-2247-2257
40-6606-66180-2997-3006
50-8258-82700-3746-3755
60-9909-99220-4495-4504
70-11561-115740-5244-5253
80-13212-132260-5993-6002
90-14864-148780-6742-6751
100-16516-165300-7492-7500

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%2.010.00.016.7%2.018.00.010.0%3.026.00.010.3%3.026.00.010.3%
Book Value Change Per Share0.04.00.00.0%3.09.00.025.0%4.016.00.020.0%8.018.03.027.6%8.018.03.027.6%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.029.00.0%0.00.029.00.0%
Total Gains per Share0.04.00.00.0%3.09.00.025.0%4.016.00.020.0%8.018.03.027.6%8.018.03.027.6%

Fundamentals of Iterum Therapeutics PLC

About Iterum Therapeutics PLC

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Fundamental data was last updated by Penke on 2024-04-11 12:20:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Iterum Therapeutics PLC.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Iterum Therapeutics PLC earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Iterum Therapeutics PLC to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Iterum Therapeutics PLC:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-2,781.1%+2,781.1%
5Y-2,781.1%10Y-3,386.2%+605.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--200.1%+200.1%
TTM--216.8%+216.8%
YOY--288.3%+288.3%
5Y-2,781.1%-449.1%-2,332.0%
10Y-3,386.2%-605.5%-2,780.7%
1.1.2. Return on Assets

Shows how efficient Iterum Therapeutics PLC is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Iterum Therapeutics PLC to the Biotechnology industry mean.
  • -47.1% Return on Assets means that Iterum Therapeutics PLC generated $-0.47 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Iterum Therapeutics PLC:

  • The MRQ is -47.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -24.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-47.1%TTM-24.5%-22.6%
TTM-24.5%YOY-15.3%-9.2%
TTM-24.5%5Y-30.6%+6.1%
5Y-30.6%10Y-28.7%-1.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-47.1%-13.3%-33.8%
TTM-24.5%-12.8%-11.7%
YOY-15.3%-11.7%-3.6%
5Y-30.6%-13.9%-16.7%
10Y-28.7%-15.7%-13.0%
1.1.3. Return on Equity

Shows how efficient Iterum Therapeutics PLC is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Iterum Therapeutics PLC to the Biotechnology industry mean.
  • 0.0% Return on Equity means Iterum Therapeutics PLC generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Iterum Therapeutics PLC:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-84.2%+84.2%
TTM-84.2%YOY-32.5%-51.7%
TTM-84.2%5Y-45.9%-38.3%
5Y-45.9%10Y-40.8%-5.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.9%+16.9%
TTM-84.2%-16.1%-68.1%
YOY-32.5%-15.1%-17.4%
5Y-45.9%-19.3%-26.6%
10Y-40.8%-20.2%-20.6%

1.2. Operating Efficiency of Iterum Therapeutics PLC.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Iterum Therapeutics PLC is operating .

  • Measures how much profit Iterum Therapeutics PLC makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Iterum Therapeutics PLC to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Iterum Therapeutics PLC:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-2,748.9%+2,748.9%
5Y-2,748.9%10Y-3,352.6%+603.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--296.2%+296.2%
TTM--232.5%+232.5%
YOY--298.2%+298.2%
5Y-2,748.9%-492.1%-2,256.8%
10Y-3,352.6%-632.4%-2,720.2%
1.2.2. Operating Ratio

Measures how efficient Iterum Therapeutics PLC is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Iterum Therapeutics PLC:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y27.707-27.707
5Y27.70710Y45.276-17.569
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.231-3.231
TTM-3.310-3.310
YOY-3.890-3.890
5Y27.7075.739+21.968
10Y45.2767.876+37.400

1.3. Liquidity of Iterum Therapeutics PLC.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Iterum Therapeutics PLC is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.89 means the company has $1.89 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Iterum Therapeutics PLC:

  • The MRQ is 1.893. The company is able to pay all its short-term debts. +1
  • The TTM is 3.900. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ1.893TTM3.900-2.007
TTM3.900YOY84.079-80.179
TTM3.9005Y19.251-15.350
5Y19.25110Y15.093+4.157
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8933.890-1.997
TTM3.9004.173-0.273
YOY84.0795.344+78.735
5Y19.2516.126+13.125
10Y15.0936.448+8.645
1.3.2. Quick Ratio

Measures if Iterum Therapeutics PLC is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Iterum Therapeutics PLC to the Biotechnology industry mean.
  • A Quick Ratio of 3.11 means the company can pay off $3.11 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Iterum Therapeutics PLC:

  • The MRQ is 3.109. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.346. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.109TTM6.346-3.237
TTM6.346YOY139.853-133.507
TTM6.3465Y31.580-25.235
5Y31.58010Y24.101+7.479
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.1093.514-0.405
TTM6.3463.998+2.348
YOY139.8535.380+134.473
5Y31.5806.105+25.475
10Y24.1016.404+17.697

1.4. Solvency of Iterum Therapeutics PLC.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Iterum Therapeutics PLC assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Iterum Therapeutics PLC to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.24 means that Iterum Therapeutics PLC assets are financed with 124.4% credit (debt) and the remaining percentage (100% - 124.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Iterum Therapeutics PLC:

  • The MRQ is 1.244. The company is just not able to pay all its debts by selling its assets. -1
  • The TTM is 0.923. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ1.244TTM0.923+0.321
TTM0.923YOY0.494+0.429
TTM0.9235Y1.111-0.188
5Y1.11110Y0.820+0.291
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2440.339+0.905
TTM0.9230.336+0.587
YOY0.4940.271+0.223
5Y1.1110.366+0.745
10Y0.8200.389+0.431
1.4.2. Debt to Equity Ratio

Measures if Iterum Therapeutics PLC is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Iterum Therapeutics PLC to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Iterum Therapeutics PLC:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM4.700-4.700
TTM4.700YOY1.015+3.684
TTM4.7005Y1.554+3.145
5Y1.55410Y1.138+0.417
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.388-0.388
TTM4.7000.402+4.298
YOY1.0150.335+0.680
5Y1.5540.426+1.128
10Y1.1380.461+0.677

2. Market Valuation of Iterum Therapeutics PLC

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Iterum Therapeutics PLC generates.

  • Above 15 is considered overpriced but always compare Iterum Therapeutics PLC to the Biotechnology industry mean.
  • A PE ratio of -0.54 means the investor is paying $-0.54 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Iterum Therapeutics PLC:

  • The EOD is -0.421. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.535. Based on the earnings, the company is expensive. -2
  • The TTM is -0.449. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.421MRQ-0.535+0.114
MRQ-0.535TTM-0.449-0.086
TTM-0.449YOY-0.295-0.154
TTM-0.4495Y-0.334-0.115
5Y-0.33410Y-0.364+0.029
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.421-2.264+1.843
MRQ-0.535-2.629+2.094
TTM-0.449-2.680+2.231
YOY-0.295-4.145+3.850
5Y-0.334-6.257+5.923
10Y-0.364-6.254+5.890
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Iterum Therapeutics PLC:

  • The EOD is -0.418. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.531. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.410. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.418MRQ-0.531+0.113
MRQ-0.531TTM-0.410-0.121
TTM-0.410YOY-0.577+0.167
TTM-0.4105Y-0.821+0.410
5Y-0.82110Y-0.714-0.107
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.418-2.973+2.555
MRQ-0.531-3.333+2.802
TTM-0.410-3.553+3.143
YOY-0.577-5.605+5.028
5Y-0.821-8.376+7.555
10Y-0.714-8.865+8.151
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Iterum Therapeutics PLC is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -4.13 means the investor is paying $-4.13 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Iterum Therapeutics PLC:

  • The EOD is -3.252. Based on the equity, the company is expensive. -2
  • The MRQ is -4.134. Based on the equity, the company is expensive. -2
  • The TTM is 0.432. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-3.252MRQ-4.134+0.881
MRQ-4.134TTM0.432-4.565
TTM0.432YOY0.308+0.124
TTM0.4325Y-0.938+1.370
5Y-0.93810Y-0.540-0.398
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.2521.896-5.148
MRQ-4.1342.115-6.249
TTM0.4322.093-1.661
YOY0.3082.884-2.576
5Y-0.9383.542-4.480
10Y-0.5403.916-4.456
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Iterum Therapeutics PLC.

3.1. Institutions holding Iterum Therapeutics PLC

Institutions are holding 9.204% of the shares of Iterum Therapeutics PLC.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Apollon Financial LLC1.48860.15522000002000000
2023-12-31New Leaf Venture Partners, L.L.C.0.72260.15419708400
2023-12-31Renaissance Technologies Corp0.37160.00024992230006.3936
2023-09-30Citadel Advisors Llc0.1456019566195660
2023-12-31Susquehanna International Group, LLP0.1305017533-30123-63.2092
2023-12-31Royal Bank of Canada0.0744010000100000
2023-12-31Morgan Stanley - Brokerage Accounts0.040805479-8471-60.724
2023-12-31UBS Group AG0.03680494949490
2023-12-31Wells Fargo & Co0.00960128500
2023-12-31Goss Wealth Management LLC0.0007010000
2023-12-31Cypress Capital Management, LLC0.00050.00016600
2023-12-31Ancora Advisors LLC0.000303800
2023-12-31Larson Financial Group, LLC0.000101300
2023-12-31Advisor Group Holdings, Inc.0.0001012-12-50
2023-12-31HM Payson & Co00300
2023-09-30Sabby Management LLC000-75000-100
2023-12-31Tower Research Capital LLC000-22-100
2023-09-30Apollon Wealth Management, LLC000-200000-100
Total 3.02220.3096406050-76113-18.7%

3.2. Funds holding Iterum Therapeutics PLC

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Fidelity Nasdaq Composite Index0.03740.0001613900
Total 0.03740.0001613900.0%

3.3. Insider Transactions

Insiders are holding 1.853% of the shares of Iterum Therapeutics PLC.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-12-22Michael W DunneBUY250001.4
2023-11-22Michael W DunneBUY200002.03
2023-11-20Corey N FishmanBUY100001.59

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Iterum Therapeutics PLC compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.732-0.640-13%-0.414-43%-0.290-60%-0.016-98%
Book Value Per Share---0.4770.430-211%2.848-117%0.769-162%1.747-127%
Current Ratio--1.8933.900-51%84.079-98%19.251-90%15.093-87%
Debt To Asset Ratio--1.2440.923+35%0.494+152%1.111+12%0.820+52%
Debt To Equity Ratio---4.700-100%1.015-100%1.554-100%1.138-100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.920-0.758-18%-0.827-10%-1.236+34%-1.160+26%
Free Cash Flow Per Share---0.927-0.725-22%-0.345-63%-0.769-17%-0.837-10%
Free Cash Flow To Equity Per Share---0.884-0.706-20%-0.376-57%-0.226-74%0.337-362%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---29.980--------
Intrinsic Value_10Y_min---25.545--------
Intrinsic Value_1Y_max---1.992--------
Intrinsic Value_1Y_min---1.956--------
Intrinsic Value_3Y_max---6.757--------
Intrinsic Value_3Y_min---6.435--------
Intrinsic Value_5Y_max---12.451--------
Intrinsic Value_5Y_min---11.491--------
Market Cap20824870.000-27%26467738.00016259856.965+63%10127604.520+161%29271972.634-10%30521243.092-13%
Net Profit Margin----0%-0%-27.8110%-33.8620%
Operating Margin----0%-0%-27.4890%-33.5260%
Operating Ratio----0%-0%27.707-100%45.276-100%
Pb Ratio-3.252+21%-4.1340.432-1057%0.308-1443%-0.938-77%-0.540-87%
Pe Ratio-0.421+21%-0.535-0.449-16%-0.295-45%-0.334-38%-0.364-32%
Price Per Share1.550-27%1.9701.210+63%0.754+161%2.177-10%2.270-13%
Price To Free Cash Flow Ratio-0.418+21%-0.531-0.410-23%-0.577+9%-0.821+55%-0.714+34%
Price To Total Gains Ratio-2.117+21%-2.691-2.076-23%-1.987-26%-1.676-38%-1.640-39%
Quick Ratio--3.1096.346-51%139.853-98%31.580-90%24.101-87%
Return On Assets---0.471-0.245-48%-0.153-67%-0.306-35%-0.287-39%
Return On Equity----0.8420%-0.3250%-0.4590%-0.4080%
Total Gains Per Share---0.732-0.640-13%-0.414-43%-0.290-60%-0.016-98%
Usd Book Value---6403000.0005778750.000-211%38267250.000-117%10372900.000-162%23507724.138-127%
Usd Book Value Change Per Share---0.732-0.640-13%-0.414-43%-0.290-60%-0.016-98%
Usd Book Value Per Share---0.4770.430-211%2.848-117%0.769-162%1.747-127%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.920-0.758-18%-0.827-10%-1.236+34%-1.160+26%
Usd Free Cash Flow---12457478.070-9739398.018-22%-4633750.000-63%-10342279.604-17%-11253503.175-10%
Usd Free Cash Flow Per Share---0.927-0.725-22%-0.345-63%-0.769-17%-0.837-10%
Usd Free Cash Flow To Equity Per Share---0.884-0.706-20%-0.376-57%-0.226-74%0.337-362%
Usd Market Cap20824870.000-27%26467738.00016259856.965+63%10127604.520+161%29271972.634-10%30521243.092-13%
Usd Price Per Share1.550-27%1.9701.210+63%0.754+161%2.177-10%2.270-13%
Usd Profit---12362000.000-9592750.000-22%-11108500.000-10%-16475250.000+33%-15497620.690+25%
Usd Revenue----0%-0%1850.000-100%48758.621-100%
Usd Total Gains Per Share---0.732-0.640-13%-0.414-43%-0.290-60%-0.016-98%
 EOD+2 -6MRQTTM+7 -21YOY+6 -225Y+8 -2210Y+8 -22

4.2. Fundamental Score

Let's check the fundamental score of Iterum Therapeutics PLC based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.421
Price to Book Ratio (EOD)Between0-1-3.252
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than13.109
Current Ratio (MRQ)Greater than11.893
Debt to Asset Ratio (MRQ)Less than11.244
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.471
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Iterum Therapeutics PLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.265
Ma 20Greater thanMa 501.592
Ma 50Greater thanMa 1001.512
Ma 100Greater thanMa 2001.656
OpenGreater thanClose1.600
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Total Stockholder Equity 27,999-9,04218,957-11,8287,129-3,6973,432-9,835-6,403



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets26,259
Total Liabilities32,662
Total Stockholder Equity-6,403
 As reported
Total Liabilities 32,662
Total Stockholder Equity+ -6,403
Total Assets = 26,259

Assets

Total Assets26,259
Total Current Assets25,596
Long-term Assets663
Total Current Assets
Cash And Cash Equivalents 6,071
Short-term Investments 17,859
Net Receivables 233
Other Current Assets 1,433
Total Current Assets  (as reported)25,596
Total Current Assets  (calculated)25,596
+/-0
Long-term Assets
Property Plant Equipment 600
Long-term Assets Other 29
Long-term Assets  (as reported)663
Long-term Assets  (calculated)629
+/- 34

Liabilities & Shareholders' Equity

Total Current Liabilities13,518
Long-term Liabilities19,144
Total Stockholder Equity-6,403
Total Current Liabilities
Short-term Debt 365
Accounts payable 4,996
Other Current Liabilities 8,157
Total Current Liabilities  (as reported)13,518
Total Current Liabilities  (calculated)13,518
+/-0
Long-term Liabilities
Long term Debt 18,956
Long-term Liabilities Other 188
Long-term Liabilities  (as reported)19,144
Long-term Liabilities  (calculated)19,144
+/-0
Total Stockholder Equity
Common Stock135
Retained Earnings -461,298
Accumulated Other Comprehensive Income 1
Other Stockholders Equity 454,759
Total Stockholder Equity (as reported)-6,403
Total Stockholder Equity (calculated)-6,403
+/-0
Other
Capital Stock135
Cash and Short Term Investments 23,930
Common Stock Shares Outstanding 13,180
Liabilities and Stockholders Equity 26,259
Net Debt 13,438
Net Invested Capital 12,553
Net Working Capital 12,078
Property Plant and Equipment Gross 366
Short Long Term Debt Total 19,509



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
26,917
0
0
0
46,757
68,131
145,470
116,865
97,871
89,134
71,293
50,942
25,751
42,312
31,687
26,270
32,792
115,165
106,045
98,422
91,509
84,063
76,687
71,555
66,833
58,120
51,021
39,728
26,259
26,25939,72851,02158,12066,83371,55576,68784,06391,50998,422106,045115,16532,79226,27031,68742,31225,75150,94271,29389,13497,871116,865145,47068,13146,75700026,917
   > Total Current Assets 
25,862
0
0
0
44,173
65,385
141,713
112,817
84,671
76,818
59,224
36,869
4,801
28,619
18,076
12,059
14,508
104,233
96,398
90,213
81,344
76,381
70,926
66,652
60,838
54,246
47,653
38,527
25,596
25,59638,52747,65354,24660,83866,65270,92676,38181,34490,21396,398104,23314,50812,05918,07628,6194,80136,86959,22476,81884,671112,817141,71365,38544,17300025,862
       Cash And Cash Equivalents 
24,809
0
0
0
8,485
38,258
84,901
39,598
44,551
64,603
51,241
28,883
4,801
23,257
12,250
8,570
14,508
66,640
36,573
35,982
27,446
31,361
9,209
20,489
21,092
16,831
13,734
4,816
6,071
6,0714,81613,73416,83121,09220,4899,20931,36127,44635,98236,57366,64014,5088,57012,25023,2574,80128,88351,24164,60344,55139,59884,90138,2588,48500024,809
       Short-term Investments 
404
0
0
0
30,731
21,376
50,370
68,509
40,000
4,997
780
1,023
1,139
1,211
1,278
1,334
0
33,868
57,155
52,022
53,935
43,909
59,700
43,866
39,747
34,992
30,998
31,076
17,859
17,85931,07630,99834,99239,74743,86659,70043,90953,93552,02257,15533,86801,3341,2781,2111,1391,0237804,99740,00068,50950,37021,37630,731000404
       Net Receivables 
245
0
0
0
509
502
889
480
721
614
740
1,878
1,111
1,106
824
757
865
806
994
1,027
1,205
413
448
795
513
308
127
170
233
2331701273085137954484131,2051,0279948068657578241,1061,1111,878740614721480889502509000245
       Other Current Assets 
808
0
0
0
4,448
5,249
6,442
2,808
7,144
6,126
6,813
6,790
5,703
4,072
4,246
1,398
2,876
2,919
1,676
1,182
1,922
698
1,569
1,502
1,338
2,423
2,921
2,465
1,433
1,4332,4652,9212,4231,3381,5021,5696981,9221,1821,6762,9192,8761,3984,2464,0725,7036,7906,8136,1267,1442,8086,4425,2494,448000808
   > Long-term Assets 
0
0
0
0
2,584
2,746
3,757
4,048
13,200
12,316
12,069
14,073
20,950
13,693
13,611
14,211
18,284
10,932
9,647
8,209
10,165
7,682
5,761
4,903
5,995
3,874
3,368
1,201
663
6631,2013,3683,8745,9954,9035,7617,68210,1658,2099,64710,93218,28414,21113,61113,69320,95014,07312,06912,31613,2004,0483,7572,7462,5840000
       Property Plant Equipment 
0
0
0
0
747
737
735
716
700
675
648
609
572
533
496
461
421
387
202
138
91
62
46
34
69
62
69
59
600
60059696269344662911382023874214614965335726096486757007167357377470000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,435
3,006
2,577
2,148
1,719
1,290
861
0
0
008611,2901,7192,1482,5773,0063,43500000000000000000000
       Long-term Assets Other 
0
0
0
0
1,837
2,009
3,022
1,824
11,541
10,768
11,421
13,464
20,378
13,160
13,115
13,750
17,863
10,545
9,445
8,071
10,165
4,614
3,138
2,721
4,207
2,522
2,438
710
29
297102,4382,5224,2072,7213,1384,61410,1658,0719,44510,54517,86313,75013,11513,16020,37813,46411,42110,76811,5411,8243,0222,0091,8370000
> Total Liabilities 
4,219
0
0
0
7,263
8,401
26,940
22,767
26,249
37,504
46,717
54,038
51,989
84,053
80,476
82,173
83,351
83,648
58,850
45,974
41,275
35,428
32,801
39,006
38,834
39,163
43,892
36,296
32,662
32,66236,29643,89239,16338,83439,00632,80135,42841,27545,97458,85083,64883,35182,17380,47684,05351,98954,03846,71737,50426,24922,76726,9408,4017,2630004,219
   > Total Current Liabilities 
4,219
0
0
0
7,126
8,323
12,290
8,031
12,219
17,618
28,253
37,332
36,986
47,090
40,616
40,866
28,865
43,809
34,378
17,829
6,058
10,081
7,493
7,509
196
7,797
10,829
16,396
13,518
13,51816,39610,8297,7971967,5097,49310,0816,05817,82934,37843,80928,86540,86640,61647,09036,98637,33228,25317,61812,2198,03112,2908,3237,1260004,219
       Short-term Debt 
0
0
0
0
0
0
14,505
0
1,019
2,056
3,496
4,997
5,800
5,917
5,983
6,158
6,488
6,621
5,035
3,244
1,627
0
292
305
332
341
348
314
365
36531434834133230529201,6273,2445,0356,6216,4886,1585,9835,9175,8004,9973,4962,0561,019014,505000000
       Short Long Term Debt 
0
0
0
0
0
0
14,505
0
1,019
2,056
3,496
4,997
5,800
5,917
5,983
6,158
6,488
6,621
5,035
3,244
1,627
0
0
0
0
0
0
0
0
000000001,6273,2445,0356,6216,4886,1585,9835,9175,8004,9973,4962,0561,019014,505000000
       Accounts payable 
1,481
0
0
0
3,152
3,575
8,169
2,708
4,041
6,176
10,160
14,527
15,486
6,301
2,246
2,645
816
1,853
1,944
276
878
684
787
1,229
2,774
2,235
3,715
5,514
4,996
4,9965,5143,7152,2352,7741,2297876848782761,9441,8538162,6452,2466,30115,48614,52710,1606,1764,0412,7088,1693,5753,1520001,481
       Other Current Liabilities 
2,738
0
0
0
3,974
4,748
4,121
5,323
7,046
442
481
645
3,042
28,307
28,409
29,834
28,865
33,097
26,126
12,478
6,058
9,397
6,706
6,280
-2,578
5,562
7,114
10,882
8,157
8,15710,8827,1145,562-2,5786,2806,7069,3976,05812,47826,12633,09728,86529,83428,40928,3073,0426454814427,0465,3234,1214,7483,9740002,738
   > Long-term Liabilities 
0
0
0
0
137
78
14,650
14,736
26,249
19,886
18,464
16,706
51,989
36,963
39,860
41,307
54,486
39,839
24,472
28,145
35,217
25,347
25,308
31,497
38,638
31,366
33,063
19,900
19,144
19,14419,90033,06331,36638,63831,49725,30825,34735,21728,14524,47239,83954,48641,30739,86036,96351,98916,70618,46419,88626,24914,73614,650781370000
       Long term Debt Total 
0
0
0
0
0
0
14,505
14,541
13,079
12,139
10,771
9,343
7,625
29,812
20,931
21,653
22,462
6,094
5,339
0
0
0
8,502
0
0
0
0
0
0
0000008,5020005,3396,09422,46221,65320,93129,8127,6259,34310,77112,13913,07914,54114,505000000
       Other Liabilities 
0
0
0
0
80
78
145
195
951
630
630
629
630
630
630
630
47,500
4,947
3,818
3,608
3,436
8,867
1,735
1,282
0
0
0
0
0
000001,2821,7358,8673,4363,6083,8184,94747,50063063063063062963063095119514578800000
> Total Stockholder Equity
22,698
22,693
0
0
39,494
59,730
118,530
94,098
71,622
51,630
24,576
-3,096
-26,238
-41,741
-48,789
-55,903
-50,559
31,517
47,195
52,448
50,234
48,635
43,886
32,549
27,999
18,957
7,129
3,432
-6,403
-6,4033,4327,12918,95727,99932,54943,88648,63550,23452,44847,19531,517-50,559-55,903-48,789-41,741-26,238-3,09624,57651,63071,62294,098118,53059,73039,4940022,69322,698
   Common Stock
4
0
0
0
4
78
142
142
144
144
144
149
149
149
179
212
494
1,787
1,826
1,827
1,827
1,833
1,835
122
126
128
130
130
135
1351301301281261221,8351,8331,8271,8271,8261,7874942121791491491491441441441421427840004
   Retained Earnings Total Equity000000-388,728000-378,052-385,850-286,929-275,743-263,544-251,023-234,923-211,282-180,011-152,3730-107,536-82,630000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-65
-96
-129
-164
-201
-236
-275
-314
-353
-392
-431
0
0
0
0
0
0
0
0
0
-350
-131
-26
3
1
13-26-131-350000000000-431-392-353-314-275-236-201-164-129-96-650000
   Capital Surplus 
0
0
0
0
0
126,535
201,018
201,492
203,271
203,859
204,443
208,037
208,536
209,133
214,576
219,628
235,876
415,580
423,421
0
0
0
430,779
0
0
0
0
0
0
000000430,779000423,421415,580235,876219,628214,576209,133208,536208,037204,443203,859203,271201,492201,018126,53500000
   Treasury Stock00000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
94,292
126,631
201,147
201,656
203,472
204,095
204,718
208,351
208,889
209,525
215,007
219,628
235,876
415,580
423,421
424,932
426,900
428,795
430,779
450,264
451,150
451,776
452,084
452,235
454,759
454,759452,235452,084451,776451,150450,264430,779428,795426,900424,932423,421415,580235,876219,628215,007209,525208,889208,351204,718204,095203,472201,656201,147126,63194,2920000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-1,750
Gross Profit-1,750-1,750
 
Operating Income (+$)
Gross Profit-1,750
Operating Expense-45,718
Operating Income-47,468-47,468
 
Operating Expense (+$)
Research Development38,242
Selling General Administrative7,476
Selling And Marketing Expenses0
Operating Expense45,71845,718
 
Net Interest Income (+$)
Interest Income0
Interest Expense-1,428
Other Finance Cost-485
Net Interest Income-943
 
Pretax Income (+$)
Operating Income-47,468
Net Interest Income-943
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-37,758-57,178
EBIT - interestExpense = -48,896
-37,758
-36,943
Interest Expense1,428
Earnings Before Interest and Taxes (EBIT)-47,468-36,330
Earnings Before Interest and Taxes (EBITDA)-45,718
 
After tax Income (+$)
Income Before Tax-37,758
Tax Provision-572
Net Income From Continuing Ops-31,099-38,330
Net Income-38,371
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses47,468
Total Other Income/Expenses Net9,710943
 

Technical Analysis of Iterum Therapeutics PLC
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Iterum Therapeutics PLC. The general trend of Iterum Therapeutics PLC is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Iterum Therapeutics PLC's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Iterum Therapeutics PLC.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.93 < 2.34 < 2.5.

The bearish price targets are: 1.42 > 1.41 > 1.26.

Tweet this
Iterum Therapeutics PLC Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Iterum Therapeutics PLC. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Iterum Therapeutics PLC Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Iterum Therapeutics PLC. The current macd is -0.01157895.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Iterum Therapeutics PLC price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Iterum Therapeutics PLC. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Iterum Therapeutics PLC price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Iterum Therapeutics PLC Daily Moving Average Convergence/Divergence (MACD) ChartIterum Therapeutics PLC Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Iterum Therapeutics PLC. The current adx is 18.69.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Iterum Therapeutics PLC shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Iterum Therapeutics PLC Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Iterum Therapeutics PLC. The current sar is 1.77414098.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Iterum Therapeutics PLC Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Iterum Therapeutics PLC. The current rsi is 49.26. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Iterum Therapeutics PLC Daily Relative Strength Index (RSI) ChartIterum Therapeutics PLC Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Iterum Therapeutics PLC. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Iterum Therapeutics PLC price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Iterum Therapeutics PLC Daily Stochastic Oscillator ChartIterum Therapeutics PLC Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Iterum Therapeutics PLC. The current cci is -39.68956337.

Iterum Therapeutics PLC Daily Commodity Channel Index (CCI) ChartIterum Therapeutics PLC Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Iterum Therapeutics PLC. The current cmo is -1.56792926.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Iterum Therapeutics PLC Daily Chande Momentum Oscillator (CMO) ChartIterum Therapeutics PLC Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Iterum Therapeutics PLC. The current willr is -69.76744186.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Iterum Therapeutics PLC is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Iterum Therapeutics PLC Daily Williams %R ChartIterum Therapeutics PLC Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Iterum Therapeutics PLC.

Iterum Therapeutics PLC Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Iterum Therapeutics PLC. The current atr is 0.11439836.

Iterum Therapeutics PLC Daily Average True Range (ATR) ChartIterum Therapeutics PLC Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Iterum Therapeutics PLC. The current obv is 3,373,999.

Iterum Therapeutics PLC Daily On-Balance Volume (OBV) ChartIterum Therapeutics PLC Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Iterum Therapeutics PLC. The current mfi is 18.52.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Iterum Therapeutics PLC Daily Money Flow Index (MFI) ChartIterum Therapeutics PLC Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Iterum Therapeutics PLC.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-31SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-11CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-12BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-19MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-21MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside

6.3. Candlestick Patterns

Iterum Therapeutics PLC Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Iterum Therapeutics PLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.265
Ma 20Greater thanMa 501.592
Ma 50Greater thanMa 1001.512
Ma 100Greater thanMa 2001.656
OpenGreater thanClose1.600
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Iterum Therapeutics PLC with someone you think should read this too:
  • Are you bullish or bearish on Iterum Therapeutics PLC? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Iterum Therapeutics PLC? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Iterum Therapeutics PLC

I send you an email if I find something interesting about Iterum Therapeutics PLC.


Comments

How you think about this?

Leave a comment

Stay informed about Iterum Therapeutics PLC.

Receive notifications about Iterum Therapeutics PLC in your mailbox!